@drclaymoss's hormone fatigue claims, fact-checked

What did @drclaymoss actually say?

Dr. Clay Moss made several distinct claims in this video. First, that the FDA "quietly removed the heart disease warning from testosterone therapy." Second, that the Traverse Trial, with over 5,000 participants, proved cardiovascular risk from TRT is "complete BS." Third, that both men and women lose testosterone with age and that current generations have historically low levels. Finally, he framed TRT as a legitimate tool for fatigue, brain fog, and low motivation when symptoms don't respond to lifestyle changes. He also disclosed he's not currently on TRT himself due to fertility goals, which is a rare and appreciated moment of personal transparency in this genre of content.

Does the science back this up?

Mostly yes, with important nuance. The Traverse Trial data is real and significant. But calling the cardiovascular concern "complete BS" oversimplifies what was actually a more complicated regulatory and scientific history.

The Traverse Trial (Lincoff et al., 2023, New England Journal of Medicine) was a landmark randomized controlled trial of 5,246 men with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk. It found testosterone replacement was non-inferior to placebo for major adverse cardiac events. That's meaningful. The FDA did subsequently update labeling in 2024 to remove the blanket cardiovascular warning that had been in place since 2015.

However, the 2015 warning wasn't invented from thin air. It came from studies like Finkle et al. (2014, PLOS ONE), which found elevated heart attack risk in the 90 days after initiating TRT prescriptions. That research had real methodological limitations, but it wasn't fabricated fear mongering. Context matters here.

On declining testosterone levels across generations, the data is real. Travison et al. (2007, Journal of Clinical Endocrinology and Metabolism) documented a population-level decline in testosterone independent of aging, though researchers still debate how much of this reflects obesity, sedentary behavior, or environmental exposures.

What did they get right, and what did they miss?

Credit where it's due: the Traverse Trial citation is accurate, the FDA labeling change is real, and his framing of lifestyle-first is responsible. The acknowledgment that women lose testosterone with age and may be candidates for therapy is also clinically grounded, even if the evidence base for women's TRT is thinner than for men.

What he missed: the Traverse Trial studied men who already had cardiovascular disease or high risk. Generalizing its findings to healthy 35-year-olds optimizing their hormones is a logical stretch the study wasn't designed to support. The trial also found a statistically significant increase in pulmonary embolism and atrial fibrillation in the testosterone group, something the video didn't mention at all.

Saying the FDA "quietly" removed the warning implies regulatory stealth. In reality, the FDA's label revision followed a formal review process tied directly to the Traverse Trial submission. That's how drug labeling is supposed to work, not a quiet burial of inconvenient data.

The symptom list in the caption, fatigue, brain fog, low motivation, is vague enough to describe dozens of conditions. Attributing these symptoms to hormones without mentioning thyroid disorders, sleep apnea, depression, or anemia as equally plausible causes is a meaningful omission when you're funneling people toward a lab-ordering link.

What should you actually know?

The science on TRT has genuinely improved, and the previous cardiovascular warning was based on weaker evidence than it deserved. The Traverse Trial matters. But "the science has spoken" is too clean a conclusion for a literature that still has open questions.

If you're experiencing fatigue, brain fog, or low motivation, a hormone panel is a reasonable thing to check. It's not the only reasonable thing to check. A thorough workup also includes thyroid function (TSH, free T4), a complete blood count, iron studies, vitamin D, fasting glucose, and a sleep history. Jumping straight to hormone optimization without ruling out these conditions can delay an accurate diagnosis.

TRT is not risk-free. Polycythemia (elevated red blood cell mass), infertility in men, and cardiovascular events in specific populations remain real considerations that require monitoring. For women, the evidence base for testosterone therapy is less robust, and appropriate dosing ranges are still being studied. Anyone considering TRT should work with a clinician who will follow their labs over time, not just initiate treatment based on a single panel.

The "optimization" framing used throughout this video treats a normal age-related hormone decline as a medical problem requiring treatment. Whether declining testosterone in someone without clinical hypogonadism warrants intervention is a genuinely contested clinical question, not a settled one.